Familial Amyloid Polyneuropathy
Familial Amyloid Polyneuropathy (FAP) is a rare genetic disorder caused by the buildup of amyloid proteins in the nerves, leading to symptoms such as pain, numbness, and weakness in the limbs.
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy: ION-682884 Study
We are assessing the long-term safety and effectiveness of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. This study aims to understand how well the treatment works over time.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you a female who is non-pregnant and non-lactating?
- Are you a male who is surgically sterile or abstinent?
- Are you willing to take vitamin A supplements as required by the study?
- Do you have any major health conditions that could make you unsuitable for this study?
- Are you between 18 and 75 years old?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ion 682884
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
The Cyprus Foundation For Muscular Dystrophy Research
Neuroepidemiology Department
Ágios Dométios, Cyprus
Centre Hospitalier Universitaire De Toulouse
Neurology
Blagnac, France
Bicetre Hospital
Neurology
Croulebarbe, France
Sponsor: Ionis Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.